In the Chinese pharmaceutical industry, there were 2 private equity deals announced in Q4 2023, worth a total value of $210m, according to GlobalData’s Deals Database. The $210m investment by Highlight Capital, Temasek Holdings and True Light Home for the Aged in Viva Biotech Holdings was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
Smarter leaders trust GlobalData
In value terms, private equity deal activity in China increased by 366% in Q4 2023 compared with the previous quarter’s total of $45.1m. Related deal volume increased by 100% in Q4 2023 versus the previous quarter.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in 2023 – Thematic Intelligence, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.
